🇺🇸 FDA
Pipeline program

Placebo for efgartigimod, ARGX-113

ARGX-113-2409

Phase 3 small_molecule active

Quick answer

Placebo for efgartigimod, ARGX-113 for Chronic Idiopathic thrombocytopenic purpura is a Phase 3 program (small_molecule) at Argenx with 1 ClinicalTrials.gov record(s).

Program details

Company
Argenx
Indication
Chronic Idiopathic thrombocytopenic purpura
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials